Prevalence, serological features, response to treatment and outcome of critical peripheral ischaemia in a cohort of lupus patients

Rheumatology

Volumn 47, Issue 9, 2008, Pages 1379-1383

  Jeffery, R C ^a   Narshi, C B ^b   Isenberg, D A ^b,c  

^a NORTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anti phospholipid syndrome; B cell depletion therapy; Digital ischaemia; Epoprostenol; Gangrene; Rituximab; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; ATORVASTATIN; BETA CALCITONIN GENE RELATED PEPTIDE; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; ENOXAPARIN; HEPARIN; ILOPROST; METHYLPREDNISOLONE; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; PROSTACYCLIN; RITUXIMAB; ROFECOXIB; WARFARIN;

ADOLESCENT; ADULT; AMPUTATION; ANTIBODY BLOOD LEVEL; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; AUTOAMPUTATION; CLINICAL FEATURE; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG PULSE THERAPY; DRUG TREATMENT FAILURE; FEMALE; GANGRENE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LUNG EMBOLISM; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PERIPHERAL ISCHEMIA; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VASCULITIS;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; FINGERS; GANGRENE; HUMANS; ISCHEMIA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TOES; TREATMENT OUTCOME;

EID: 50849110170     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken210     Document Type: Article

References (37)

1. Ehrenstein MR, Isenberg DA. Systemic lupus erythematosus in adults - clinical features and aetiopathogenesis. Oxford textbook of rheumatology, 3rd edn. Oxford: Oxford University Press, 2004:826-7.
2. Iqbal S, Sher MR, Good RA, Cawkwell GD. Diversity in presenting manifestations of systemic lupus erythematosus in children. J Pediatr 1999;135:500-5.
3. Rothwell PM, Coull AJ. Silver LE. et al., for the Oxford Vascular Study. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005,366:1773-83.
4. Shortel CK, Ouriel K, Green RM, Condemi JJ, De Weese JA. Vascular disease in the antiphospholipid syndrome: A comparison to the patient population with atherosclerosis. J Vasc Surg 1992;15:158-65.
5. Bruce IN, 'Not only... but also': Factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 2005;44:1492-502.
6. Toloza SM, Uribe AG, McGwin G Jr et al. LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004;50:3947-57.
7. Lima DS, Sato El, Lima VC, Miranda F Jr, Hatta FH. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002;29:292-7.
8. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
9. Sebastiani GD, Galeazzi M, Tincani A et al. Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. Scand J Rheumatol 1999;28:344-51.
10. Drenkard C, Villa AR, Reyes E, Abello M, Alarcon-Segovia D. Vasculitis in systemic lupus erythematosus. Lupus 1997;6:235-42.
11. Gallli M, Barbui T. Antiphospholipid antibodies and thrombosis: Strength of association. Hematol J 2003;4:180-6.
12. Petri M, Rheinschmidt M, Whiting-O'Keefe Q, Hellmann D, Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann Intern Med 1987; 106:524-31.
13. Naldi L, Locati F, Marchesi L et al. Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: A case-control study. Ann Rheum Dis 1993;52:219-22.
14. Diogenes MJ, Diogenes PC, de Morais Carneiro RM, Neto CC, Duarte FB, Holanda RR. Cutaneous manifestations associated with antiphospholipid syndrome. Int J Dermatol 2004;43:632-7.
15. Riccieri V, Spadaro A, Ceccarelli F, Scrivo R, Germano V, Valesini G. Nailfold capillaroscopy changes in systemic lupus erythematosus: correlations with disease activity and autoantibody profile. Lupus 2005;14:521-5.
16. Furtado RN, Pucinelli ML, Cristo VV, Andrade LE, Sato EI, Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud's phenomenon in SLE patients. Lupus 2002;11:35-41.
17. Duthois S, Cailleux N, Benosman B, Levesque H. Tolerance of Iloprost and results of treatment of chronic severe lower limb ischaemia in diabetic patients. A retrospective study of 64 consecutive cases. Diabetes Metab 2003;29:36-43.
18. Meini S, De Franco V, Auteri A, Setacci C, DiRenzo M, Pieragalli D. Short-term and long-term effects of one-week treatment with intravenous iloprost in critical limb ischaemia patients (Leriche-Fontaine stage III and IV): Int Angiol 2005;24:64-9.
19. Fiessinger JN, Schafer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangitis obliterans. Lancet 1990;335:555-7.
20. Bozkurt AK, Koksal C, Demirbas MY et al. Turkish Buerger's Disease Research Group. A randomised trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease. Int Angiol 2006;25:162-8.
21. Wigley FM, Wise RA, Seibold JR et al. Intravenous Iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicentre, placebo-controlled, double blind study. Ann Intern Med 1994;120:199-206.
22. Scorza R, Rivolta R, Mascaghi B et al. Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis. J Rheumatol 1997;24:1944-8.
23. Saniabadi AR, Belch JJ, Lowe GD, Barbenel JC, Forbes CD. Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood. Haemostasis 1987;17:147-53.
24. Candela M, Pansoni A, Jannino L et al. Coagulative modifications in patients with systemic sclerosis treated with iloprost or nifedipine. Ann Ital Med Int 2001;16:170-4.
25. Delta Bella S, Molteni M, Mocellin C, Fumagalli S, Bonara P, Scorza R. Novel mode of action of iloprost: In vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins 2001;65:73-83.
26. Czeslick EG, Simm A, Grond S, Silber RE, Sablotzki A. Inhibibon of intracellular tumour necrosis factor (TNF)-alpha and interleukin (IL)-6 production in human monocytes by iloprost. Eur J Clin Invest 2003;33:1013-7.
27. DiRenzo M, Pieragalli D, Meini S et al. Iloprost treatment reduces TNF-alpha production and TNF-RII expression in critical limb ischaemia patients without affecting IL-6. Prostaglandins Leukot Essent Fatty Acids 2005;73:405-10.
28. Torley HI. Madholk R, Capell HA et al. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 1991;50:800-4.
29. Veale DJ, Muir AH, Morley KD, Belch JJ. Treatment of vasculitic leg ulcers in connective tissue disease with iloprost. Clin Rheumatol 1995;14:187-90.
30. Zahavi J, Charach G, Schafer R, Toeg A, Zuhavi M. Ischaemic necrotic toes associated with antiphospholipid syndrome and treated with iloprost. Lancet 1993;342:862.
31. Zulian F, Corona F, Gerloni V et al. Safety and efficacy of iloprost for the treatment of ischaemia in paediatric connective tissue diseases. Rheumatology 2004;43:229-33.
32. Harada N, Okajima K, Uchiba M. Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischaemia-reperfusion-induced liver injury in rats. Crit Care Med 2006;34:2011-3.
33. Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet 1990; 336:1530-3.
34. Bunker CB, Reavley C, O'Shaughnessy DJ, Dowd PM. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon, Lancet 1993;342:80-3.
35. Tomietto P, Grenese E, Tolusso B, Venturini P, DeVita S, Ferraccioli G. B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus. Thromb Haemost 2004;92:1150-3.
36. Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebmann H. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 2006;33:255-7.
37. Ioannou Y, Lambrianides A, Cambridge G, Leandro MJ, Edwards JC, Isenberg DA. B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis 2008;67:425-6.